Gazyva may become a standard treatment for older, sicker patient with CLL.
All News
All series
All All News
Advertisement
Patients with multiple myeloma fare better with continuous Revlimid (lenalidomide).
The Memory and Attention Adaptation Training (MAAT) program was designed to improve the quality of life and function of cancer survivors who are experiencing post-therapy cognitive issues.
Advertisement
Brain cancer researchers and advocates join resources to help tackle this rare and aggressive malignancy.
Patients battling cancer get financial assistance from friends, family, social media and non-profit organizations.
Advertisement
Advertisement
Trending on CURE
1
FDA Updates Safety Warnings for Common Chemotherapy Drugs
2
KTX-1001 Elicits Responses in Some With Multiple Myeloma
3
FDA Removes Use Limitation for Yescarta in Primary CNS Lymphoma
4
New Combination Treatment Approach Studied in Pancreatic Cancer
5